导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.19% | 3997/4773 |
| 近一周 | -3.21% | 3891/5462 |
| 近一月 | -3.27% | 1662/5421 |
| 近一季 | -2.11% | 1174/5209 |
| 近半年 | -5.59% | 2902/4920 |
| 近一年 | -16.55% | 3801/4366 |
| 近两年 | 27.37% | 2398/2954 |
| 近三年 | 7.96% | 1795/2253 |
| 成立以来 | 19.92% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.61% 4674/4961 |
8.55% 2582/5312 |
- - |
- - |
| 2025 | 3.28% 3137/4813 |
-6.74% 3392/3635 |
4.15% 849/4076 |
10.81% 3241/4524 |
-4.04% 3380/4813 |
| 2024 | 27.11% 201/3463 |
-4.81% 1771/2808 |
-8.29% 2206/3014 |
40.45% 61/3129 |
3.67% 782/3463 |
| 2023 | 3.63% 268/2656 |
3.90% 1098/2280 |
-2.83% 683/2385 |
7.33% 48/2515 |
-4.36% 982/2655 |
| 2022 | -24.95% 1275/2207 |
-17.65% 1236/1919 |
1.78% 1422/2016 |
-15.44% 1293/2113 |
5.89% 417/2208 |
| 2021 | -3.71% 925/1822 |
-14.17% 1169/1255 |
6.43% 749/1330 |
3.97% 390/1466 |
1.37% 952/1822 |
| 2020 | 18.05% 749/1250 |
-9.20% 662/1028 |
8.80% 810/1067 |
18.14% 88/1164 |
1.14% 1041/1184 |
| 2019 | - - |
- - |
- - |
-4.38% 770/850 |
10.02% 171/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝券商ETF联接C VS. 长安沪深300非周期A(740101) |